New therapies for glaucoma

Are they all up to the task?

Thomas Yorio, Adnan Dibas

Research output: Contribution to journalReview articleResearchpeer-review

1 Citation (Scopus)

Abstract

This review summarises the patenting activity in the anti-glaucoma field for the period 2001 - 2004. The various patents are classified based on the targeted mechanism of claimed drugs. New drugs, especially in the area of neuroprotection, are covered. Whereas some of the patent applications represent new areas in the treatment of glaucoma, others represent improved or modified classes of current anti-glaucoma drugs given to patients. However, most of the patent applications lack clinical data and some even lack data supporting their glaucoma efficacy claims. The authors have attempted to highlight, where possible, a number of promising drugs for the treatment of glaucoma. These are not all inclusive and represent the authors bias in selection. Some areas that were not included (e.g., calcium channel blockers, K+ channel agents, etc) are still equally important.

Original languageEnglish
Pages (from-to)1743-1762
Number of pages20
JournalExpert Opinion on Therapeutic Patents
Volume14
Issue number12
DOIs
StatePublished - 1 Dec 2004

Fingerprint

Glaucoma
Pharmaceutical Preparations
Therapeutics
Patents
Selection Bias
Calcium Channel Blockers

Keywords

  • Glaucoma
  • Intraocular pressure
  • Neuroprotection
  • Therapeutics

Cite this

@article{6f6df199d161446083d77dcb474ec5b2,
title = "New therapies for glaucoma: Are they all up to the task?",
abstract = "This review summarises the patenting activity in the anti-glaucoma field for the period 2001 - 2004. The various patents are classified based on the targeted mechanism of claimed drugs. New drugs, especially in the area of neuroprotection, are covered. Whereas some of the patent applications represent new areas in the treatment of glaucoma, others represent improved or modified classes of current anti-glaucoma drugs given to patients. However, most of the patent applications lack clinical data and some even lack data supporting their glaucoma efficacy claims. The authors have attempted to highlight, where possible, a number of promising drugs for the treatment of glaucoma. These are not all inclusive and represent the authors bias in selection. Some areas that were not included (e.g., calcium channel blockers, K+ channel agents, etc) are still equally important.",
keywords = "Glaucoma, Intraocular pressure, Neuroprotection, Therapeutics",
author = "Thomas Yorio and Adnan Dibas",
year = "2004",
month = "12",
day = "1",
doi = "10.1517/13543776.14.12.1743",
language = "English",
volume = "14",
pages = "1743--1762",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

New therapies for glaucoma : Are they all up to the task? / Yorio, Thomas; Dibas, Adnan.

In: Expert Opinion on Therapeutic Patents, Vol. 14, No. 12, 01.12.2004, p. 1743-1762.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - New therapies for glaucoma

T2 - Are they all up to the task?

AU - Yorio, Thomas

AU - Dibas, Adnan

PY - 2004/12/1

Y1 - 2004/12/1

N2 - This review summarises the patenting activity in the anti-glaucoma field for the period 2001 - 2004. The various patents are classified based on the targeted mechanism of claimed drugs. New drugs, especially in the area of neuroprotection, are covered. Whereas some of the patent applications represent new areas in the treatment of glaucoma, others represent improved or modified classes of current anti-glaucoma drugs given to patients. However, most of the patent applications lack clinical data and some even lack data supporting their glaucoma efficacy claims. The authors have attempted to highlight, where possible, a number of promising drugs for the treatment of glaucoma. These are not all inclusive and represent the authors bias in selection. Some areas that were not included (e.g., calcium channel blockers, K+ channel agents, etc) are still equally important.

AB - This review summarises the patenting activity in the anti-glaucoma field for the period 2001 - 2004. The various patents are classified based on the targeted mechanism of claimed drugs. New drugs, especially in the area of neuroprotection, are covered. Whereas some of the patent applications represent new areas in the treatment of glaucoma, others represent improved or modified classes of current anti-glaucoma drugs given to patients. However, most of the patent applications lack clinical data and some even lack data supporting their glaucoma efficacy claims. The authors have attempted to highlight, where possible, a number of promising drugs for the treatment of glaucoma. These are not all inclusive and represent the authors bias in selection. Some areas that were not included (e.g., calcium channel blockers, K+ channel agents, etc) are still equally important.

KW - Glaucoma

KW - Intraocular pressure

KW - Neuroprotection

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=10344222102&partnerID=8YFLogxK

U2 - 10.1517/13543776.14.12.1743

DO - 10.1517/13543776.14.12.1743

M3 - Review article

VL - 14

SP - 1743

EP - 1762

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 12

ER -